Pamela M. Arway Sells 1,264 Shares of Davita Inc (DVA) Stock

Davita Inc (NYSE:DVA) Director Pamela M. Arway sold 1,264 shares of Davita stock in a transaction on Thursday, June 7th. The shares were sold at an average price of $68.76, for a total transaction of $86,912.64. Following the completion of the sale, the director now owns 39,235 shares in the company, valued at approximately $2,697,798.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of DVA stock opened at $71.76 on Wednesday. Davita Inc has a 12 month low of $52.51 and a 12 month high of $80.71. The firm has a market cap of $12.58 billion, a PE ratio of 21.61, a price-to-earnings-growth ratio of 1.05 and a beta of 1.10. The company has a current ratio of 2.94, a quick ratio of 2.90 and a debt-to-equity ratio of 1.94.

Davita (NYSE:DVA) last announced its earnings results on Thursday, May 3rd. The company reported $1.05 EPS for the quarter, beating the Zacks’ consensus estimate of $0.92 by $0.13. Davita had a net margin of 2.94% and a return on equity of 13.84%. The firm had revenue of $2.85 billion for the quarter, compared to analysts’ expectations of $2.79 billion. During the same quarter in the previous year, the business posted $0.79 EPS. The company’s quarterly revenue was up 8.3% on a year-over-year basis. analysts expect that Davita Inc will post 4.1 earnings per share for the current year.



Several analysts recently weighed in on the stock. SunTrust Banks reiterated a “hold” rating and issued a $80.00 price target on shares of Davita in a report on Wednesday, February 14th. Zacks Investment Research cut shares of Davita from a “buy” rating to a “hold” rating in a report on Tuesday, February 13th. Robert W. Baird set a $97.00 price target on shares of Davita and gave the company a “buy” rating in a report on Tuesday, February 13th. Finally, William Blair reiterated a “buy” rating on shares of Davita in a report on Wednesday, June 6th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, five have given a buy rating and two have given a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $81.22.

Several hedge funds have recently made changes to their positions in the company. Dimensional Fund Advisors LP boosted its holdings in shares of Davita by 1.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,762,205 shares of the company’s stock valued at $182,141,000 after buying an additional 32,357 shares in the last quarter. OppenheimerFunds Inc. boosted its holdings in shares of Davita by 36.7% during the 1st quarter. OppenheimerFunds Inc. now owns 2,561,970 shares of the company’s stock valued at $168,937,000 after buying an additional 688,052 shares in the last quarter. Boston Partners boosted its holdings in shares of Davita by 39.7% during the 1st quarter. Boston Partners now owns 2,036,058 shares of the company’s stock valued at $134,258,000 after buying an additional 578,242 shares in the last quarter. Millennium Management LLC raised its position in shares of Davita by 239.9% in the 4th quarter. Millennium Management LLC now owns 2,024,308 shares of the company’s stock worth $146,256,000 after purchasing an additional 1,428,810 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Davita by 1.0% in the 4th quarter. Geode Capital Management LLC now owns 1,609,652 shares of the company’s stock worth $116,051,000 after purchasing an additional 16,017 shares during the last quarter. Hedge funds and other institutional investors own 87.71% of the company’s stock.

Davita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Insider Buying and Selling by Quarter for Davita (NYSE:DVA)

Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply